Prevention of recurrent aphthous stomatitis by efalizumab (Raptiva®) [27]

Journal of the European Academy of Dermatology and Venereology

Volumn 21, Issue 9, 2007, Pages 1286-1287

  Zribi, H ^a   Crickx, B ^a   Descamps, Vincent ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EFALIZUMAB; ETANERCEPT; ETRETIN; METHOTREXATE;

ADULT; APHTHOUS STOMATITIS; APHTHOUS ULCER; CASE REPORT; CLINICAL FEATURE; DRUG WITHDRAWAL; HUMAN; LETTER; MALE; OUTCOME ASSESSMENT; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS VULGARIS; RECURRENT DISEASE;

ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; RECURRENCE; STOMATITIS, APHTHOUS;

EID: 34548801287     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2007.02182.x     Document Type: Letter

References (5)

1. Scully C. Clinical practice. Aphthous ulceration. N Engl J Med 2006; 355: 165-172.
2. +high T regulatory cells in peripheral blood of patients with recurrent aphthous ulcerations. Immunol Lett 2005; 99: 57-62.
3. Pedersen A, Ryder LP. T-cell fraction of peripheral blood is increased in recurrent aphthous ulceration. Clin Immunol Immunopathol 1994; 72: 98-104.
4. Dubertret L, Sterry W, Bos JD et al. CLEAR Multinational Study Group. CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: Results from a phase III international randomized, placebo-controlled trial. Br J Dermatol 2006; 155: 170-181.
5. Robinson ND, Guitart J. Recalcitrant, recurrent aphthous stomatitis treated with etanercept. Arch Dermatol 2003; 139: 1259-1262.